Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18 years, including males and females;
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2;
Life expectancy of ≥3 months;
Does not have diabetes and has normal fasting serum glucose and fasting triglycerides ≤ 300 mg/dL
For women of child-bearing potential, negative serum pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to the first study drug administration to 30 days following the last study drug administration;
Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 30 days following the last study drug administration;
Ability to swallow oral medications;
Ability to understand and willingness to sign informed consent form prior to initiation of any study procedures;
You may not be if
Have received prior cancer therapy or other investigational therapy within 2 weeks prior to the first administration of study drug.
Known impaired cardiac function or clinically significant cardiac disease
HIV infection;
Failed to recover from the reversible effects of prior anticancer therapies:
Pregnancy (positive serum or urine pregnancy test) or breast feeding;
Malabsorption due to prior gastrointestinal (GI) surgery, GI disease;
Clareo Health | Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia
